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The outcome of multimodal therapy for localized bladder rhabdomyosarcoma is quite good in terms of
morbidity, and conservative surgery is generally recommended. However, in cases originating in the
bladder neck, tumorectomy or partial cystectomy has adverse effects on bladder function. A 2-year-old
girl underwent transurethral resection of a bladder tumor (TUR-BT), chemotherapy consisting of
vincristine, actinomycin-D, and cyclophosphamide, and radiotherapy. She was in remission for 3 years
when frequent urination became evident. Her bladder capacity and compliance were low; however, her
urinary symptom was controlled using anticholinergic medication. Accordingly, TUR-BT could be an
optional approach for bladder rhabdomyosarcoma.
 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rhabdomyosarcoma is the most common pediatric soft tissue
sarcoma. Approximately 10e15% of all rhabdomyosarcoma cases
arise from the pelvic organs [1]. The tumor is often large and in-
volves adjacent organs and vessels. Histologically, bladder/prostate
rhabdomyosarcoma is typically either embryonal or botryoid.
After chemotherapy, radical surgery is required; this is usually
urinary reconstruction or diversion, except for tumors arising at the
top of the bladder [2]. Recently, multimodal treatment with che-
moradiotherapy and surgery has led to a good prognosis. Therefore,
conservative surgery (subtotal/partial resection) is generally rec-
ommended [2]. Laparotomy is often used for bladder/prostateof a bladder tumor; CT,
rcoma Study; SIOP, Interna-
Mesenchymal Tumors.
ata).
Inc. This is an open access article urhabdomyosarcoma; however, transurethral resection of a bladder
tumor (TUR-BT) can be applied to preserve the organ when the
tumor is growing into the bladder, provided that the residual dis-
ease can be treated with chemoradiotherapy. Herein, we describe a
patient with bladder rhabdomyosarcoma that was resected using
TUR-BT.
2. Case report
A 23-month-old girl presented with macroscopic hematuria and
a vulval mass. At admission, enhanced computed tomography (CT)
indicated a solid mass measuring 32  30  26 mm that occupied
the bladder (Fig. 1A and B) without metastasis. A biopsy was per-
formed using cystoscopy and showed increased numbers of rhab-
domyoblasts and polygonal-shaped cells with eosinophilic
cytoplasm (Fig. 1G and H). She was diagnosed with botryoid
embryonal rhabdomyosarcoma, group III, stage 2, and vincristine,
actinomycin-D, and cyclophosphamide (VAC) therapy was admin-
istered [3]. The tumor shrank (Fig. 1C and D), and TUR-BT was
performed after 8 weeks. The tumor was localized in the bladdernder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Computed tomography and histopathological ﬁndings. A, B: An enhanced solid mass measuring 32  30  26 mm occupying the bladder (white arrow). C, D: An enhanced
mass remained in the bladder neck (white arrow). E, F: Wall thickening of the bladder neck after chemoradiotherapy (white arrow). G, H: Rhabdomyoblasts and polygonal-shaped
cells with eosinophilic cytoplasm increased pathologically.
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muscle layer of the bladder neck. After surgery, chemotherapy and
radiotherapy was administered. The proton beam was used to
irradiate the residual tumor site at 50.4 Gy (RBE: relative biological
effectiveness) and the entire bladder was irradiated with 30.6 Gy
(RBE). At the end of therapy, enhanced CT indicated that the bladder
neckwall was still thickened (Fig.1E and F). Therefore, an additional
biopsy was transurethrally performed, which showed that this
thickened lesion consisted of ﬁbrotic tissue that did not contain
viable cells. There has been no relapse of the tumor 3 years after the
end of treatment.
After discharge, the patient developed persistent increased
urinary frequency and transient urinary hemorrhage. Two years
after therapy, voiding cystography indicated that the bladder ca-
pacity was 84 mL (56%) at 4 years of age (normal level 150 mL)
(Fig. 2A) [4] and the bladder neck wall was irregular. A urodynamics
study indicated an intravesical pressure of 16 cmH2O at the
maximum bladder volume of 83 mL (Fig. 2B). This resulted in a
poorly compliant bladder. However, the symptom was controlled
using anticholinergic medication and restriction of ﬂuid intake.3. Discussion
The appropriate treatment strategy for bladder/prostate rhab-
domyosarcoma is combined modality treatment with chemo-
radiotherapy and surgery. The prognosis of localized embryonal
bladder/prostate rhabdomyosarcoma is good [5], and conservative
therapy improves patients’ quality of life, as demonstrated by
clinical trials [6]. However, organ preservation in the surgical pro-
cess remains controversial. Conservative surgery includes tumor-
ectomy, partial prostatectomy, partial cystectomy, or both partial
prostatectomy and cystectomy, in which the posterior urethra is
spared. Radical surgery is typically performed with margin-free
tumor resection with concordant removal of the bladder and theposterior urethra, and is associated with lymph node dissection [7].
Filipas et al. stated that conservative surgery carries high risks of
positive margins and tumor relapse, and that radical surgery and
current techniques of continent urinary diversion are beneﬁcial [2].
However, Alexander et al. showed no difference between conser-
vative and radical surgery in terms of the 5-year overall and event-
free survival of patients with bladder/prostate rhabdomyosarcomas
[8]. In the Intergroup Rhabdomyosarcoma Study (IRS) IV study, the
overall survival rate of patients with nonmetastatic bladder/pros-
tate rhabdomyosarcoma was 82% (72/88). Fifteen of 88 patients
needed urinary diversion [6]. In the International Society of Pedi-
atric Oncology (SIOP) study, the overall 5-year survival rate of pa-
tients with nonmetastatic bladder/prostate rhabdomyosarcoma
was 73% [7]. In both studies, organ preservation surgery was used.
Cystoscopy for bladder rhabdomyosarcoma is usually performed
only for biopsy or exploration, and not for deﬁnitive surgery,
because the rhabdomyosarcoma arises from the muscle layer of the
bladder. TUR-BT was performed for transitional cell carcinoma in
children, as well as in adults [9,10]. Complications of this procedure
include postoperative bleeding and perforation of the bladder wall.
In particular, surgeons must be careful of excessive resection of
tumors arising from the bladder wall. Although potentially carrying
the risk of residual disease, TUR-BT may be sufﬁcient for local
control of bladder rhabdomyosarcoma, when patients are properly
treated with postoperative radiotherapy.
It is speculated that the cause of incontinence after conservative
surgical therapy for bladder/prostate rhabdomyosarcoma is the
origin of a tumor or tissue damage due to radiotherapy. For con-
servative surgery, radiotherapy with consideration of both
curability and tissue damage mitigation is an important factor.
Proton beams and brachytherapy have been reported to be useful
methods for reducing tissue damage by radiation therapy. For
bladder/prostate primary tumors, when there is a residual tumor,
50.4 Gy (RBE) of external irradiation is required; however,
Fig. 2. Voiding cystography and urodynamics study. A: Voiding cystography indicated the bladder capacity was 84 mL (56%) (normal level 150 mL) and the bladder neck wall was
irregular. B: A urodynamics study indicated intravesical pressure measured 16 cmH2O at the maximum bladder volume of 83 mL.
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proton beam has the potential to reduce the exit dose to areas other
than the target area. Cotter et al. compared the radiation doses in
the pelvic tissues in proton beam therapy and Intensity Modulated
Radiation Therapy at the time of planning with consideration of
radiation to bladder/prostate rhabdomyosarcoma cases; they
showed the superiority of proton beams. In addition, 7 patients
received treatment based on the IRS and survived [11].
Brachytherapy was also a method to reduce radiation compli-
cations. With this method, a high dose can be used at a short dis-
tance. Martelli et al. showed the result of brachytherapy to prostate
and/or bladder neck rhabdomyosarcoma in combination with the
MMT 89, 95, 98, RMS 2005 protocol. The survival ratewas as high as
92% (24/26). However, the authors decided that brachytherapy was
not suitable for tumors invading beyond the bladder triangle.
Eighteen patients over the age of 4 years were normally continent
[12]. Urinary function after treatment was also good; however, the
indication for brachytherapy was limited and brachytherapy was
not considered suitable for our case. Chargari et al. showed the
result of brachytherapy to 100 patients with bladder neck and/or
prostate rhabdomyosarcoma in combination with the IRS protocol.
The 5-year disease-free and overall survival rates were 84%. Most
survivors presented with only mild to moderate genitourinary
sequelae and normal diurnal urinary continence [13].
The long-term prognosis of conservative therapy requires
consideration of clinical symptoms and objective evaluation of
urinary function.
In the IRS IV study, only 49.3% of patients who underwent
bladder/prostate preservation had normal urinary function [6].
Urinary disorders included dribbling, enuresis, and incontinence.
Factors affecting urinary disorders were tumor origin, radiation,
cystitis, hemorrhagic cystitis, intraoperative nerve injury, and
bladder atrophy. Organ-preserving surgery was structurally ach-
ieved. However, the bladder function was appropriately examined
and voiding cystography and urodynamics studies are required in
future studies.4. Conclusion
In conclusion, we encountered a case of a bladder neck rhab-
domyosarcoma that was successfully treated with TUR-BT. TUR-BT
may be a conservative surgical option for bladder neck rhabdo-
myosarcomas that are growing intraluminally. Patients receiving
organ-preserving surgery should undergo objective examinationsfor urinary function, such as urodynamic studies and voiding cys-
tography, and long-term follow-up is required. A large-scale study
is necessary to obtain evidence of the safety and effectiveness of
TUR-BT.
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